To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004

NCT06169059 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult

Interventions

DRUG: JLP-2004
DRUG: JC-013

Sponsor

Jeil Pharmaceutical Co., Ltd.